STOCK TITAN

Ainos, Inc. - $AIMD STOCK NEWS

Welcome to our dedicated page for Ainos news (Ticker: $AIMD), a resource for investors and traders seeking the latest updates and insights on Ainos stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Ainos's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Ainos's position in the market.

Rhea-AI Summary
Ainos, Inc. announces $10 million private placement with Lind Global Fund II LP. Initial conversion price set at $1.50 per share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Summary
Ainos' VELDONA receives Orphan Drug Designation for oral warts in HIV-seropositive patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.47%
Tags
-
Rhea-AI Summary
Ainos, Inc. has received Orphan Drug Designation for its VELDONA® low-dose oral interferon formulation as a potential treatment for oral warts in HIV-seropositive patients. The estimated 24,000 HIV-seropositive Americans suffering from oral warts could benefit from this new treatment option. Ainos plans to pursue Phase III clinical studies for the drug candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.3%
Tags
Rhea-AI Summary
Ainos, Inc. has started shipping its VELDONA® Pet cytoprotein supplements in Taiwan, with plans to deliver 300,000 units by October. The company aims to scale up capacity to meet increasing demand and has expanded distribution in various channels, including Taiwanese e-commerce platforms, pet supply stores, chain drugstores, and convenience stores. Ainos expects VELDONA® Pet to generate $20 million in sales in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.97%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.68%
Tags
AI
-
Rhea-AI Summary
Ainos, Inc. announced its financial results for Q2 2023, revealing a shift in strategic focus from COVID to pet health and AI-powered testing. The company launched VELDONA® Pet, a pet health supplement line, and made progress in the development of Ainos Flora, a VOC POCT device. Revenues for Q2 2023 were $28,555, compared to $636,627 in the same period last year. Gross profit was negative $27,262, and net loss attributable to common stock shareholders was $2,349,727.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.22%
Tags
none
-
Rhea-AI Summary
Ainos partners with Nisshinbo Micro Devices and Taiwan Inabata Sangyo to co-develop a volatile organic compound (VOC) sensing platform. Ainos will be compensated with an upfront development fee and per-unit fees. The partnership aims to create a new standard in VOC sensing and analysis utilizing Ainos' AI algorithm and digital nose technologies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.49%
Tags
partnership
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
none
Rhea-AI Summary
Ainos, Inc. announces its AI-powered digital nose technology, AI Nose, which integrates artificial intelligence with digital nose sensors. The technology can accurately identify volatile organic compounds (VOCs) associated with specific diseases, making it ideal for non-invasive point-of-care testing (POCT). Ainos is currently conducting clinical trials for its flagship VOC POCT device, Ainos Flora, and expects to complete them by the end of 2023. The company aims to capitalize on the growing telehealth industry and the projected US$256 billion STI testing market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.98%
Tags
AI
Ainos, Inc.

Nasdaq:AIMD

AIMD Rankings

AIMD Stock Data

6.39M
2.56M
54.71%
0.32%
1.32%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
SAN DIEGO